our milestones
2026
• Expanded global presence across Africa, the Middle East, Latin America, CIS countries, and Asia. • Strengthened international contract manufacturing and private label partnerships. • Launched Cura Consultants to provide end-to-end regulatory, GMP compliance, SOP development, and international audit readiness services. • Expanded the Group's diversified portfolio through Oluline Essentials Private Limited, focusing on Ayurvedic, herbal, wellness, and personal care products. • Strengthened domestic healthcare operations through Shashwat Pharma, specializing in critical care and hospital products across India.
2025
• Expanded manufacturing partnerships with WHO-GMP, EU-GMP, and internationally accredited facilities. • Enhanced capabilities in pharmaceuticals, nutraceuticals, veterinary healthcare, cosmetics, and herbal formulations. • Introduced new product categories including effervescent nutraceuticals, specialty injectables, and innovative wellness solutions. • Strengthened regulatory support services, including dossier preparation, product registrations, and technical documentation for global markets.
2024
• Expanded presence into new international markets through strategic distribution partnerships. • Enhanced regulatory support for semi-regulated and regulated markets. • Strengthened private label and contract manufacturing capabilities for pharmaceutical and nutraceutical products.
2023
• Expanded presence into new international markets through strategic distribution partnerships. • Enhanced regulatory support for semi-regulated and regulated markets. • Strengthened private label and contract manufacturing capabilities for pharmaceutical and nutraceutical products.
2022
• Established long-term partnerships with internationally accredited manufacturing facilities. • Strengthened export operations with comprehensive end-to-end project management, from product development to global logistics.
2021
• Expanded global sourcing and manufacturing network to support increasing international demand. • Enhanced quality management systems and regulatory compliance processes.
2020
• Successfully maintained uninterrupted global supply of essential healthcare products during the COVID-19 pandemic. • Supported international customers with timely deliveries and regulatory assistance during unprecedented global challenges.
2015-2017
• Diversified operations into veterinary healthcare, cosmetics, and herbal formulations. • Built strategic alliances with manufacturing partners to broaden product offerings.
2018-2019
• Expanded portfolio into nutraceuticals, wellness products, and consumer healthcare. • Strengthened capabilities in private labeling, packaging development, and branding solutions.
2010-2014
• Established a strong foundation in international pharmaceutical exports. • Developed expertise in regulatory documentation, product registrations, and market-specific compliance.